Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers November 23, 2014
Pharmacy Choice - News - Front Page Healthcare News - November 23, 2014

Pharmacy News

 Front Page Healthcare News
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

11/22/14 - "Methods of Inhibiting Tumor Growth by Antagonizing Il-6 Receptor" in Patent Application Approval Process
By a News Reporter-Staff News Editor at Obesity, Fitness& Wellness Week A patent application by the inventor ZHANG, LI, filed on July 11, 2014, was made available online on November 6, 2014, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application is assigned to Regeneron Pharmaceuticals, In
11/22/14 - Centura home health care recognized [Cihan News Agency (Turkey)]
Five Centura Health at Home agencies, including Centura Health at Home in Pueblo, were named in the 2014 HomeCare Elite, a listing of the top-performing home health agencies in the U.S. Centura Health at Home Pueblo was recognized as a Top 100 agency, while Mercy Home Health in Durango is a Top 500 agency. Erin Denholm, senior vice president of cli
11/22/14 - CMS accepts Luis' systems improvement plan [The Virgin Islands Daily News, St. Thomas]
CROIX Federal regulators have signed-off on a document Luis Hospital officials submitted on Wednesday night that lays out the hospital's responsibilities as Luis staff work to correct deficiencies and meet basic standards for quality of care. If the hospital has failed, CMS may terminate the hospital's ability to participate in Medicare and Medic
11/22/14 - Florida is home to nearly 300K uninsured young adults, group reports [The Miami Herald]
Nov. 22 An estimated 330,000 Floridians between the ages of 18 and 34 are uninsured and likely to remain so unless state legislators accept the federal government's offer to fund the cost of expanding the eligibility criteria for Medicaid as called for under the Affordable Care Act, according to a brief released this week by a national nonprofit
11/22/14 - Generic drug prices skyrocket in past year [Chicago Tribune]
The 44- year-old piano tuner and guitar instructor from Elgin, who has health insurance, used to pay $20 for a three-month supply of his generic epilepsy drug as a member of Walgreen's Prescription Savings Club. But in the past year, the price of many generics is disconcertingly moving in the wrong direction, drawing the attention of Congress and p
11/22/14 - Highland Therapeutics receives second notice of allowance for patent on Lead product [EMBIN (Emerging Markets Business Information News]
Highland Therapeutics, a pharmaceutical company, announced that the US Patent and Trademark Office has issued a Notice of Allowance for a patent application for HLD-200, a novel formulation of methylphenidate designed to be taken once-daily in the evening with the objective of controlling symptoms of ADHD immediately upon awakening and throughout t
11/22/14 - Immigration Action Leaves Health Coverage Gap [Cihan News Agency (Turkey)]
Kids can go to school without worrying that their parents will be deported and not be there when they get home, says Angel Padilla, a health policy analyst with the National Immigration Law Center. Under Obama's plan, newly protected immigrants will not be eligible for public health benefits such as Medicaid, the government's program for poor or di
11/22/14 - Los Banos hospital recognized for patient care [Los Banos Enterprise (Los Banos, Calif.)]
Nov. 21 Sutter Health announced last week that Memorial Hospital, Los Banos, was among its facilities that recently received special recognition from the leading accreditor of health care organizations in the country. The hospital, along with Memorial Medical Center in Modesto and Sutter Tracy Community Hospital, has been recognized in the Joint.
11/22/14 - Sun Sentinel Michael Mayo column [Sun Sentinel]
The so-called Affordable Care Act is supposedly President Obama's signature achievement, with 6.7 million previously-uninsured Americans enrolling in the past year. But Obamacare remains under siege in almost every respect in theory, in practice, in courtrooms, in a Republican Congress emboldened by midterm election success, and in the hearts and
11/22/14 - Tekmira Provides Key Highlights of Analyst and Investor Day in New York
Tekmira Pharmaceuticals Corporation, a leading developer of RNA interference therapeutics, announced today an update from the Company's Analyst and Investor Day, which took place on November 21 in New York City. The Company announced its first regulatory filing, in the form of a Clinical Trial Application filed with Health Canada, to support its
11/22/14 - United States : FDA approves extended-release, single-entity hydrocodone product with abuse-deterrent properties [TendersInfo (India)]
Hysingla ER has approved labeling describing the product s abuse-deterrent properties consistentwith the FDA s 2013 draft guidance for industry, Abuse-Deterrent Opioids Evaluation and Labeling. The FDA has determined that the physical and chemical properties of Hysingla ER are expected to make abuse by these routes difficult. While the science of a
11/21/14 - "The Price of Global Health" Tackles Worldwide Drug-Pricing Debate
Heated dialogue in recent months about the rising cost of prescription drug prices from cancer treatments to Gilead's new hepatitis C drug Harvoni has consumers, legislators and pharmaceutical leaders around the world questioning what it means to put a price on patient treatment and quality of care. And while drug pricing is one of the m
11/21/14 - ABPI -Now is the time for a new initiative to accelerate access to medical innovations
Our research shows that 90% of clinicians and healthcare professionals believe that stratified medicine in a range of disease areas will have a positive impact on the UK's health system. And therein lies the crux of the current situation with regards to patient and professional access to innovative medicines- at present the UK health system is simp
11/21/14 - Avaxia Biologics Receives FDA Orphan Drug Designation for AVX-470 for the Treatment of Pediatric Ulcerative Colitis
Avaxia Biologics, Inc., a clinical-stage biopharmaceutical company developing gut-targeted antibody therapeutics for gastrointestinal diseases, announced today that the US Food and Drug Administration granted Orphan Drug Designation to AVX-470 for the treatment of pediatric ulcerative colitis. AVX-470 is a gut-targeted anti-TNF antibody, which...
11/21/14 - Axial Exchange Posts Results of North Carolina Patient Engagement Ranking [Health & Beauty Close - Up]
In a release, Axial Exchange said that in the North Carolina PER, Rex Hospital, Park Ridge Health and Duke Raleigh Hospital topped the list out of 82 hospitals in the state. Rex Hospital also ranked first in last year's PER announcement, issued in October 2013. The highest possible ranking a hospital can receive in the Axial Exchange PER is a score
11/21/14 - Basilea reports that U.S. FDA sets date of Advisory Committee meeting on isavuconazole NDA for the treatment of invasive aspergillosis and mucormycosis
Basel, Switzerland, November 21, 2014- Basilea Pharmaceutica Ltd. reports today that the U.S. Food and Drug Administration announced a public meeting of the Anti-Infective Drugs Advisory Committee to discuss the New Drug Application for the investigational antifungal isavuconazole, which was submitted by a subsidiary of Basilea's licensing partne
11/21/14 - Bio Blast Pharma Reports Third Quarter Financial Results
Bio Blast Pharma Ltd., a clinical-stage biotechnology company committed to developing clinically meaningful therapies for patients with rare and ultra-rare genetic diseases, today announced financial results for the third quarter ended September 30, 2014. Research and development expenses for the third quarter of 2014 were $1.23 million, compared
11/21/14 - Ceapro Appoints World Renowned Health And Disease Management Expert, William W. Li, M.D. To Board Of Directors [Global Data Point]
Through his work at the Angiogenesis Foundation, he has developed a unique social enterprise model based on international collaborations with leading medical academic centers, biopharmaceutical companies and government agencies, including the National Institutes of Health, National Cancer Institute and the Food and Drug Administration.
11/21/14 - Celgene Receives Positive CHMP Opinion for OTEZLA (apremilast), the First Oral PDE4 Inhibitor for the Treatment of Patients with Psoriasis and Psoriatic Arthritis
BOUDRY, Switzerland Celgene International Srl, a wholly-owned subsidiary of Celgene Corporation, today announced that the European Medicines Agency s Committee for Medicinal Products for Human Use has adopted a positive opinion for OTEZLA , the Company s oral selective inhibitor of phosphodiesterase 4, in two therapeutic indications:
11/21/14 - Centers for Medicare & Medicaid Services Announces Town Hall Meeting on FY 2016 Applications for New Medical Services
WASHINGTON, Nov. 21 The U.S. Department of Health and Human Services published the following notice in the Federal Register from the. A Notice by the Centers for Medicare& Medicaid Services on 11/21/2014. Centers for Medicare& Medicaid Services.
11/21/14 - Centurion Selected To Provide Comprehensive Correctional Healthcare In Vermont
Centurion, a joint venture between Centene and MHM Services Inc., will provide medical and behavioral health services to offenders and detainees housed at eight facilities throughout the state. We look forward to collaborating with the Vermont DOC and other stakeholder groups in Vermont, including the state's Medicaid plan, Green Mountain Care, to
11/21/14 - Changes to an Approved Application: Biological Products: Human Blood and Blood Components Intended for Transfusion or for Further Manufacture;...
SUMMARY: The Food and Drug Administration is announcing the availability of a document entitled "Changes to an Approved Application: Biological Products: Human Blood and Blood Components Intended for Transfusion or for Further Manufacture; Guidance for Industry" dated December 2014. The guidance announced in this notice finalizes the draft guidance
11/21/14 - CHMP Grants Positive Opinions of AbbVie's VIEKIRAX? (ombitasvir/paritaprevir/ritonavir) + EXVIERA? (dasabuvir) for the Treatment of Chronic Hepatitis C in Europe
The European Committee for Medicinal Products for Human Use of the European Medicines Agency has granted positive opinions for AbbVie's investigational, all-oral, interferon-free treatment of VIEKIRAX?+ EXVIERA? with or without ribavirin for patients with genotype 1 and genotype 4 chronic hepatitis C virus infection. "The CHMP positive opini
11/21/14 - Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva
Clementia Pharmaceuticals, Inc. announced today that the European Medicines Agency has granted Orphan Medicinal Product Designation for palovarotene, the company's lead product candidate, for the treatment of fibrodysplasia ossificans progressiva. Palovarotene, an investigational retinoic acid receptor gamma agonist, is currently in a Phase 2...
11/21/14 - Concerns voiced over shifting of 28 pharmaceutical firms to India [EMBIN (Emerging Markets Business Information News]
Senate Standing Committee on Inter-Provincial Co-ordination has expressed serious concerns over shifting of 28 multinational pharmaceutical companies to India, paying Rs 1.5 billion tax, as Drug Regulatory Authority of Pakistan is not functioning properly. Federal Minister for Inter-Provincial Co-ordination Riaz Hussain Pirzada and Secretary...
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

© 2014 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Newest and Most Current Medications in the Treatment of Diabetes
This lesson is supported by:
HIV & AIDS Testing & Reporting Guidelines
This lesson is supported by:

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Websites »
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement